drugset / Trial / NCT00296803

PROCLAIM: Study Examining Effects of Clopidogrel Compared to Placebo on Inflammation in Subjects With Metabolic Syndrome

NCT00296803 ↗

Phase 4 Completed 216 enrolled Sanofi Bristol-Myers Squibb · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the effects of clopidogrel compared to placebo on markers of inflammation in subjects with metabolic syndrome who are receiving background therapy including low dose aspirin.

Timeline

Start
2005-11
Primary completion
—
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule — —

Indications